Table 1. Crude OR and 95% CIs of the positive autoantibodies before and after treatment initiation among the studied groups of patients (A and B).

Follow-up	Patients with positive autoantibodies
	aPL (ACL or anti-β2-GPI)			ACL IgG			ACL IgM			Anti-β2-GPI IgG			ANA
	n (%)	OR	95% CIs	n (%)	OR	95% CIs	n (%)	OR	95% CIs	n (%)	OR	95% CIs	n (%)	OR	95% CIs
Group A: sodium valproate (n=30)
Before treatment	15 (50)	Baseline		3 (10)	Baseline		4 (13)	Baseline		8 (24)	Baseline		9 (30)	Baseline
6 m	7 (23)*	0.30*	0.10–0.92*	2 (7)	0.64	0.10–4.15	0 (0)	-	-	5 (17)	0.55	0.16–1.93	5 (17)	0.47	0.14–1.61
12 m	11 (36)	0.58	0.21–1.62	2 (7)	0.64	0.10–4.15	2 (7)	0.46	0.08–2.75	7 (23)	0.84	0.26–2.70	6 (20)	0.58	0.18–1.91
24 m	13 (43)	0.76	0.28–2.11	3 (10)	1.00	0.19–5.40	3 (10)	0.72	0.15–3.54	7 (23)	0.84	0.26–2.70	9 (30)	1.00	0.33–3.02
Group B: carbamazepine (n=20)
Before treatment	7 (35)	Baseline		1 (5)	Baseline		3 (15)	Baseline		3 (15)	Baseline		3 (15)	Baseline
6 m	5 (25)	0.62	0.16–2.43	0 (0)	-	-	2 (10)	0.63	0.09–4.24	3 (15)	1.00	0.18–5.67	1 (5)	0.30	0.03–3.15
12 m	9 (45)	1.52	0.43–5.43	1 (5)	1.00	0.06–17.18	4 (20)	1.42	0.27–7.34	4 (20)	1.42	0.27–7.34	1 (5)	0.30	0.03–3.15
24 m	8 (40)	1.24	0.34–4.46	0 (0)	-	-	4 (20)	1.42	0.27–7.34	4 (20)	1.42	0.27–7.34	1 (5)	0.30	0.03–3.15

^*Statistically significant associations.

ACL: anticardiolipin antibodies, ANA: antinuclear antibodies, anti-β2-GPI: anti-β2-glycoprotein I antibodies, aPL: antiphospholipid antibodies, CI: confidence interval, Ig: immunoglobulin, m: months, OR: odds ratios.